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Ipilimumab and Cancer Immunotherapy: A New
Hope for Advanced Stage Melanoma
Matthew Mansh
Stanford University School of Medicine, Stanford, California
Metastatic melanoma remains one of the most lethal and poorly treated forms of human
cancer. Its incidence is on the rise, but no therapies offering improved survival rates have
been developed over the last 40 years. This has changed with the recent Food and Drug Ad-
ministration (FDA†) approval of the CTLA-4 function blocking antibody Ipilimumab (yervoy),
proven to extend life in patients with previously treated or untreated metastatic melanoma
[39,40]. CTLA-4 is a receptor that normally functions to inhibit inappropriate or prolonged ac-
tivation of T-cells. This review presents the history of initial research into the function of the
CTLA-4 receptor, the pre-clinical evidence for CTLA-4 blockade’s utility in cancer treatment,
and  the  recent  human  clinical  trials  that  have  proven  its  efficacy  in  advanced  stage
melanoma. Ipilimumab represents one of a growing class of cancer immunotherapies cur-
rently under development and highlights both the promise and relative infancy of these
agents in the clinical setting.
INTRODUCTION
Metastatic  melanoma  has  been  de-
scribed as one of the most aggressive forms
of human cancer, and its incidence is on the
rise. It originates from uncontrolled prolif-
eration  of  specialized  melanocytes  nor-
mally responsible for producing pigments
in epithelial layers. Though typically asso-
ciated with the skin, these cells are also
present in the eye, ears, meninges, bone,
and heart, and cancer lesions can develop
in any of these locations. 
In  2010,  nearly  70,000  Americans
were diagnosed with either invasive or in
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munotherapy, immunologysitu melanoma, proving fatal in about 9,000
cases annually; 1 in 39 Caucasian males
(about 2.5 percent) born in 2010 are ex-
pected to develop melanoma in their lifetime
[1]. This rate stood at around 1 in 1,500 (or
less than .06 percent) in 1935, indicating the
dramatic  increase  in  prevalence  of
melanoma over the last century [2]. 
Despite being a rare form of skin can-
cer, melanoma accounts for nearly 75 per-
cent of skin cancer deaths. While those with
early Stage I lesions have high 3-year sur-
vival rates (more than 90 percent), individ-
uals with late-stage melanoma have a poorer
prognosis (10 percent) with a median sur-
vival of only 7.5 months after diagnosis [3].
For the last 40 years, treatment advances
have been largely stagnant. Traditional op-
tions for late-stage patients lack substantial
efficacy. These include IL-2, which shows
only a 6 percent complete response rate [4],
and dacarbazine, which produces only a 6
percent to 15 percent response rate with no
improvement in survival [5]. 
However, the landscape for late-stage
treatment options has changed recently with
the FDA approval in March 2011 of the can-
cer  immunotherapy  drug  ipilimumab  for
treatment  of  metastatic  melanoma  [6].
Widely touted as a therapeutic breakthrough,
ipilimumab works through enhancing T-cell
activity by modifying the function of the Cy-
totoxic T-Lymphocyte Antigen 4 (CTLA-4)
inhibitory receptor. Evidence for ipilimumab
offers hope for patients with a clearly lethal
disease, but also highlights some of the dan-
gers and relative infancy of immunothera-
pies in the clinical setting.
CTLA-4 AND CANCER 
IMMUNOTHERAPY
While many chemotherapy drugs target
cancer cells through manipulation of the cell
cycle and apoptosis, immunotherapy alter-
natively relies on augmentation of the im-
mune mechanisms responsible for naturally
eliminating cancer cells. This approach is
not necessarily “new,” as researchers have
been developing these agents for more than
a  century  alongside  an  explosion  in  our
knowledge of the human immune system.
As early as 1890, Paul Ehrlich proposed the
use of active immunization as a treatment
for cancer [7].
Nearly 70 years later, Sir Frank Burnet
of Australia hypothesized the concept of
cancer surveillance: the ability of the im-
mune  system  to  recognize  and  eliminate
transformed cells [8]. By the early 1990s,
Rituximab was released as the first anti-
body-based therapy for a human cancer, B-
cell  lymphoma  [9].  Other  therapies
followed,  including  IL-2  [10]  and  inter-
feron-alpha treatment [11,12]. The field is
expanding, and immunotherapies ranging
from adoptive T-cell transfer for renal cancer
[13] to radioconjugated antibodies for ma-
lignant gliomas [14] are now being tested in
the clinic. 
Recent  studies  have  shown  that
melanoma lesions often contain a high num-
ber  of  infiltrative  T-cells  specific  to
melanocyte tumor associated antigens such
as MART1, gp-100, and tyrosinase, which
are components of the melanin synthesis
pathway [15]. Augmenting the natural func-
tion  of  these  Cytotoxic  T-Lymphocytes
(CTLs) seems a logical approach to elimi-
nating melanoma cancer cells. Normal T-cell
activation requires two complementary sig-
nals.  This  includes  TCR  stimulation  by
MHC bound antigens and by interaction of
the T-cell’s CD28 receptor with the B7 re-
ceptor (CD80/CD86) found on APCs [16].
Stimulation leads to intracellular signaling
activity that helps initiate T-cell activation,
promoting the release of IL-2 and enhanc-
ing proliferation.
CTLA-4  was  discovered  in  the  late
1980s and first identified as an immunoglo-
bin found primarily on CD4+ or CD8+ T-
lymphocytes  with  a  then-unidentified
function [17]. Other studies have demon-
strated that high levels of CTLA-4 are also
important in maintaining certain subsets of
T-regulatory cells [18]. CTLA-4, like CD28,
binds B7 receptors on APCs. It alternatively
initiates inhibitory effects upon binding, in-
cluding cell cycle arrest and decreased cy-
tokine production. More importantly, some
forms of the B7 receptor show dramatically
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CD28 [19], as a single CTLA-4 receptor can
concurrently bind as many as eight B7 mol-
ecules [20]. A balancing act thus occurs be-
tween CD28/B7 mediated activating signals
and CTLA-4/B7 inhibitory signals in normal
T-cells to help initiate robust killing but also
to  serve  to  prevent  prolonged  activation
when inappropriate (Figure 1A). 
PRE-CLINICAL EVIDENCE FOR THE
DEVELOPMENT OF IPILIMUMAB
CTLA-4 became an attractive target for
immunotherapy once it was identified as a
negative regulator of T-cell activation. Pre-
clinical evidence began to provide strong
support that CTLA-4 modification could
serve as a useful approach for controlling
natural immune responses in animal models
of  common  human  malignancies.  Re-
searchers first constructed functional block-
ing and enhancing monoclonal antibodies
against murine CTLA-4. Blockade functions
in theory to remove CTLA-4 inhibitory sig-
nals  such  that  T-cell  co-activation  via
B7/CD28 interactions becomes unopposed,
leading to increased T-cell activity (Figure
1B). 
Walunas  et  al.  demonstrated  that
CTLA-4 blockade helped augment T-cell
proliferation and activation in vivo using tar-
geted antibody treatment [21]. In a complete
knockout murine model, CTLA-4 loss re-
sults in massive lymphoproliferation, organ
destruction, and death [22,23], a finding that
predicted some of the many risks associated
with CTLA-4 blockade in humans discussed
later in this review. Krummel and Allison al-
ternatively used activating antibodies and
showed that CTLA-4 activation blocked T-
cell proliferation and decreased IL-2 pro-
duction [24]. It is with these initial studies
that scientists proved capable of modulating
CTLA-4 activity in T-cells in vivo using tar-
geted antibodies. 
Researchers  next  hypothesized  that
CTLA-4 modulation might produce clini-
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Figure 1. T-cell regulation, CTLA-4,
and Ipilimumab. A) Normal T-cell acti-
vation occurs via presentation of MHC-
bound antigens on APCs that signal
through the TCR. This process is am-
plified by the co-stimulatory signal pro-
duced by interaction of the CD80/86
(B7) receptor on APCs with CD28 mol-
ecules on the T-cell. Prolonged T-cell
activation initiates the upregulation of
CTLA-4, a membrane receptor that
competes with CD28 for binding to
CD80/86 (B7). CTLA-4 has a higher
affinity for CD80/86 (B7) than CD28
and its binding oppositely produces in-
hibitory signals through decreased
proliferation and IL-2 production. This
relationship allows normal T-cells to
prevent over-activation through feed-
back upregulation of CTLA-4. B) Ipili-
mumab binds to CTLA-4 and prevents
interaction with CD80/CD86 (B7) mol-
ecules on APCs. This removes CTLA-
4 induced inhibitory signals allowing
for unregulated and prolonged activa-
tion of T-cells in a non-specific man-
ner.cally useful results in tumor models. Many
human cancers contain T-cells that are not
properly activated against target cells ex-
pressing tumor-associated antigens (TAAs),
including melanoma. It is generally thought
that these TAAs are unable to initiate suffi-
cient activating signals via the B7/CD28 and
MHC/TCR co-stimulatory pathways when
opposed by CTLA-4 [25]. Evidence shows
that T-cells isolated from mice transplanted
with a fibrosarcoma decrease their capacity
to produce lymphocytokines over the course
of a few weeks. This is rescued by CTLA-4
blockade, which increased levels of IL-2 and
INF-gamma production in a tumor stage de-
pendent manner [26]. Accordingly, a num-
ber  of  studies  were  conducted  to  test  if
CTLA-4 blockade could be used to treat
common human tumors in pre-clinical ani-
mal models.  
CTLA-4  blockade  was  first  tested
across a number of murine models of can-
cer, including prostate cancer [27], breast
cancer  [28],  and  lymphoma  [29].  Re-
searchers often found that the combination
of CTLA-4 therapy with a vaccine or some
other  immune  stimulating  factor  proved
most  efficacious.  For  instance,  using  a
prostate  cancer  mouse  model  [30],  re-
searchers were able to reduce tumor inci-
dence five-fold with a combined treatment
of a CTLA-4 antibody and an irradiated
tumor vaccine [31]. 
For melanoma, the approach to com-
bine CTLA-4 blockade with another form of
immune modulation was also considered. In
one study, mice transplanted with a poorly
immunogenic melanoma cell line showed up
to an 80 percent cure rate in recently injected
tumors when CTLA-4 antibody blockade
was combined with a GM-CSF vaccine [32].
Other  pre-clinical  research  demonstrated
that CTLA-4 inhibition paired with DNA
vaccines targeted against gp100 or tyrosi-
nase-2 worked synergistically to improve
tumor eradication [33]. Ultimately, these
works showed that augmentation of natu-
rally present CTLs in cancer tissues through
CTLA-4 blockade could provide clinical
benefit in animal models of melanoma and
other human malignancies.
THE DEVELOPMENT OF 
IPILUMUMAB AND CLINICAL 
EVIDENCE IN ADVANCED STAGE
MELANOMA
Elucidation of the basic role of CTLA-
4 in immune modulation and the success of
pre-clinical studies in murine models of can-
cer provided strong impetus for the creation
of a human CTLA-4 antibody. This set the
path  for  the  development  of  ipilimumab
(Yervoy), which originated in the lab of Dr.
James Allison, formerly of the University of
California-Berkeley. His team was one of
the first to identity and describe the role of
CTLA-4 in immune function. The lab also
developed a number of antibody-based ap-
proaches for blockade [34]. These CTLA-4
antibody technologies were acquired by a
private  biotechnology  startup,  Medarex,
through a patent acquisition in 2000. 
Medarex began recruiting for a Phase III
trial in 2004 following initial data from ear-
lier Phase I/II studies indicating ipilimumab
was safe and potentially efficacious for treat-
ment of late stage melanoma [35,36]. By
2009, Medarex became a subsidiary of phar-
maceutical giant Bristol-Meyers Squibb in
order to further commercialize ipilimumab
for  use  in  melanoma  and  other  cancers.
Pfizer was also concurrently developing its
own  CTLA-4  antibody,  tremelimumab,
which was later abandoned based off poor
Phase III results [37]. Alternatively, ipili-
mumab was granted permission to be mar-
keted to treat advanced melanoma patients in
the European Union in 2010 [38] and more
recently approved by the FDA for treatment
of metastatic melanoma in the United States.  
This decision culminated a substantial
development process that has run parallel with
a number of clinical studies for the use of ip-
ilimumab  in  many  other  human  cancers
(Table 1). The Phase III studies that supported
these advances resulted in two high profile ar-
ticles, both published in the New England
Journal  of  Medicine.  Researchers  demon-
strated that ipilimumab treatment increased
survival rates in patients both with previously
treated and untreated metastatic melanoma. 
The first trial involved a randomized,
double-blind study across 125 medical cen-
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Table 1. History of the Development of Ipilimumab
Month
January
November
September
June
April
June
July
September
November
March
November
January
october
April
May
September
August
August
November
March 22
March 25
June 5
Year
2000
2001
2002
2003
2004
2004
2004
2004
2004
2005
2006
2007
2007
2008
2009
2009
2010
2010
2010
2011
2011
2011
Development
Medarex acquires anti-CLA-4 monoclonal antibody license in the US
Phase I/II clinical trials for malignant melanoma and prostate cancer
begin in US
Phase II clinical trials for lymphoma begin in US
Phase I/II clinical trials for breast cancer begin in US
Phase II trial for renal cancer begins in US
Ipilimumab receives Orphan Drug Status for malignant melanoma in
the US
FDA approval for a Phase III study of ipilimumab for malignant
melanoma in the US
Phase III trials for melanoma begin in the US
Ipilimumab is licensed to Bristol-Myers Squibb outside of the US
Phase II trias for breast cancer begin globally
Ipilimumab receive fast-track status as a second-line treatment and as
a first-line treatment in combination with dacarbazine for malignant
melanoma in the US
Medarex completes enrollment of single arm of a Phase III trial for ma-
lignant melanoma
Phase I trial for urogenital cancer begins in US
Phase II trial for non-small cell lung cancer begins in EU and US
Phase III trials for prostate cancer begin in Australia, Canada, the EU, Latin
America, and the US
Bristol-Myers Squibb acquires Medarex for $2.1 billion
Phase III data published in NEJM supporting improved survival in pa-
tients with previously treated metastatic melanoma 
FDA sets decision deadline for December for ipilimumab
FDA postpones decision until March 2011
Bristol-Myers Squibb releases Phase III data that shows ipilimumab im-
proves 1-year survival rates in patients with previously untreated
metastatic melanoma
FDA approves ipilimumab for treatment of malignant melanoma
Phase III data officially published in NEJM supporting improved sur-
vival in patients with previously untreated metastatic melanoma 
Timeline of the development of ipilimumab along with concurrent developments for its use in other
human cancers. Particular important milestones in the development of ipilimumab relevant to
melanoma are noted in bold. Data adapted from figures and information presented in ipilimumab 2011
[38].ters, using 676 patients with Stage III/IV
melanoma  who  experienced  disease  pro-
gression after standard treatment. Patients
were  assigned  to  receive  ipilimumab,  a
gp100 peptide vaccine, or both in combina-
tion. While patients receiving peptide vac-
cine alone showed a median overall survival
time of 6.4 months, those receiving ipili-
mumab alone or in combination with the
gp100 vaccine increased survival to 10.1
months and 10.0 months respectively. Re-
sponses were limited to a small subset of pa-
tients.  In  fact,  only  about  1  percent  of
patients showed a complete response and 5
percent to 10 percent a partial response to
some form of ipilimumab treatment [39].
The release of this publication prompted the
FDA to review ipilimumab as a potential
therapy for late stage melanoma.
After a series of delays, the FDA ap-
proved ipilimumab for treatment of metasta-
tic melanoma in March 2011, coinciding
with the release of data from a second Phase
III study. In a 502-patient, double-blind,
placebo-controlled  trial,  Bristol-Myers
Squibb compared the standard of care treat-
ment (dacarbazine alone) with a combina-
tion treatment (ipilimumab + dacarbazine)
for patients with metastatic melanoma not
previously  treated.  Overall  survival  in-
creased from 9.1 months to 11.2 months
with the addition of ipilimumab, and 3-year
survival increased from 12.2 percent to 20.8
percent. However, serious side effects were
noted. About 56 percent of patients receiv-
ing combination therapy reported Grade 3 or
4 adverse events [40], compared to 27.5 per-
cent of patients receiving dacarbazine alone. 
IMMUNOLOGICAL CONSIDERATIONS
AND RISKS OF CTLA-4 BLOCKADE
While T-cells targeting melanoma anti-
gens are activated following treatment of ip-
ilimumab,  CTLA-4  blockade  also
non-specifically increases activity of all T-
cells reliant upon CTLA-4 inhibition. For
the case of ipilimumab, this may be particu-
larly relevant as it is given at doses high
enough that complete receptor saturation is
likely [41]. Consequentially, CTLA-4 block-
ade  can  lead  to  immune-related  adverse
events that can be quite serious and are a
strong criticism cited by opponents of the
antibody. This has prompted some authors
to compare the risk of ipilimumab to that of
the recently tested CD28 agonist TGN1412
[41].  Under  consideration  in  the  United
Kingdom, treatment with TGN1412 initiated
a  cytokine  storm  in  some  patients  and
caused six deaths in London during a disas-
trous clinical trial [42].
In both NEJM articles, nearly all pa-
tients suffered side effects from the treat-
ment. Most commonly, these events were
immune related but included diarrhea, nau-
sea, constipation, abdominal pain, vomiting,
vitiligo, and dermatitis. In the 2010 gp100
combination therapy trial, 14 deaths were at-
tributed to be a result of taking ipilimumab,
about half of which were related to severe
immune events [39]. However, no deaths
were reported as a result of treatment in the
second Phase III trial [40].
Adverse events are a long-standing con-
cern with ipilimumab. Case reports reveal a
number of more serious consequences rang-
ing from severe hepatitis [43] to enterocolitis
[44]. In previous studies, ipilimumab has also
induced  hypophysitis,  pancreatitis,  and
nephritis [45]. Of particular note, these events
were more common in patients with the best
tumor responses to treatment [46,47]. Con-
sistent immune monitoring thus becomes an
essential complement to ipilimumab admin-
istration. This includes monitoring cytokine
levels, specific immune responses, cell pop-
ulation levels, and cell surface markers both
in the tumor and peripherally to assess ad-
verse events and change treatment plans and
doses accordingly [48]. These immune con-
siderations remain a major obstacle to cancer
immunotherapy acceptance and highlight a
challenge in targeting these agents specifi-
cally to tumor-associated immune cells.
CONCLUSIONS AND THE FUTURE
OF MOLECULAR THERAPIES
Ipilimumab represents a significant ad-
vance  for  the  treatment  of  metastatic
melanoma and for the field of cancer im-
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ery of a novel, immune protein in an aca-
demic laboratory, it also serves as a model
example of the importance of basic science
research in driving new therapeutic avenues
of investigation. While ipilimumab provides
hope for patients with metastatic melanoma,
it is not without shortcomings. 
Ultimately, most critics take the stance
that cancer immunotherapies walk a fine and
dangerous line between increasing natural
immune responses and risking severe au-
toimmunity  [49]. This  is  apparent  in  the
widespread adverse events associated with
ipilimumab treatment. Development of better
immune system monitoring, markers for ab-
normal immune behavior, and clearer end-
points may be the best methods to overcome
these challenges [48]. The clinical benefit of
ipilimumab  also  remains  relatively  mild.
Complete  and  partial  responses  were  re-
stricted to only a small subset of patients
(about 10 percent), and ipilimumab extended
the lives of all late-stage melanoma patients
only by an average of a few months. Given
the dangerous side effects, a better under-
standing of the factors that predict response
levels to ipilimumab would serve to select
patients best suited to receive treatment.
Despite these shortfalls, ipilimumab is a
strong figure in the growing field of cancer
immunotherapy. It is also not alone. New
treatments for melanoma are still on the
horizon. Early data suggests a novel BRAF
inhibitor (vemurafenib) produces near 50
percent  response  rates  in  metastatic
melanoma patients [50]. A triple peptide
vaccine targeted against gp100, tyrosinase,
and MART-1 has also showed promising re-
sults in increasing T-cell activity in metasta-
tic melanoma patients [51]. More extreme
approaches have utilized adoptive cell ther-
apy to activate and expand melanoma-spe-
cific T-cells in vitro and transplant them
back into patients with up to 72 percent re-
sponse rates in early studies [52].
Cancer immunotherapies are novel, and
their use in the clinic is still in its infancy.
As we learn to enhance the efficacy of treat-
ments  like  ipilimumab  through  better
screening, immune monitoring, and contin-
ued clinical research, these innovative ap-
proaches will likely prove invaluable tools
against some of the most difficult human
diseases. Melanoma should likely be no ex-
ception.
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